Differential Impact of Body Mass Index on Recurrence, Cardiac Remodelling, and Quality of Life After Atrial Fibrillation Ablation: Insights From the China‐ AF Registry
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70740 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Yuexin Jiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Body Mass Index, Quality of Life, Catheter Ablation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
The impact of body mass index (BMI) on the outcomes of radiofrequency catheter ablation (RFCA), including atrial fibrillation (AF) recurrence rate, cardiac remodelling, and quality of life (QoL), remains uncertain.
Methods
We analysed 12 104 first‐time RFCA patients from the China‐AF registry, stratified by BMI: under/normal weight (< 25 kg/m 2 ), overweight (25–29.9 kg/m 2 ), and obese (≥ 30 kg/m 2 ). The primary outcome was AF recurrence. Exploratory outcomes included 12‐month echocardiographic parameters and Atrial Fibrillation Effect on Quality‐of‐Life (AFEQT) scores. Multivariable Cox regression, median regression, restricted cubic splines (RCS), and subgroup analyses were performed.
Results
In this cohort (median age 61.55 years, 32.6% female), obese patients were significantly younger with higher comorbidities burdens. Over a median follow‐up of 47.5 months, 4932 (40.8%) patients experienced AF recurrence. BMI exhibited a linear, dose‐dependent association with recurrence risk (fully adjusted HR 1.01, 95% CI, 1.00–1.02; obese HR 1.16, 95% CI: 1.05–1.28), consistent across primary analyses, sensitivity analyses using Chinese BMI classification standards, and subgroups (with stronger associations in males, < 65 years, persistent AF), without significant interactions across these subgroups (all p interaction > 0.05). Exploratory analyses suggested obesity was linked to nonlinearly higher 12‐month left ventricular end‐diastolic diameter (LVEDD; 2.17 mm, 95% CI: 0.79–3.55) and left ventricular wall thickness (LVWT; 0.81 mm, 95% CI: 0.45–1.17) versus under/normal‐weight, with nonlinear association in primary analysis (both p nonlinear < 0.05).
Conclusion
Higher BMI exhibits a linear association with AF recurrence post‐RFCA. Obesity is linked to nonlinear adverse remodelling (LVEDD and LVWT).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Changsheng Ma
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Jiang, Y., Zhou, L., He, L., Yang, L., Liu, F., Lu, S., Li, M., Jiang, C., Tang, R., Sang, C., Du, X., Long, D., Dong, J., & Ma, C. (2026). Differential Impact of Body Mass Index on Recurrence, Cardiac Remodelling, and Quality of Life After Atrial Fibrillation Ablation: Insights From the China‐ AF Registry. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70740
Vancouver
Jiang Y, Zhou L, He L, Yang L, Liu F, Lu S, et al. Differential Impact of Body Mass Index on Recurrence, Cardiac Remodelling, and Quality of Life After Atrial Fibrillation Ablation: Insights From the China‐ AF Registry. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70740
BibTeX
@article{Jiang2026,
author = {Jiang, Yuexin and Zhou, Le and He, Liu and Yang, Lirui and Liu, Fang and Lu, Shangxin and Li, Mengmeng and Jiang, Chenxi and Tang, Ribo and Sang, Caihua and Du, Xin and Long, Deyong and Dong, Jianzeng and Ma, Changsheng},
title = {Differential Impact of Body Mass Index on Recurrence, Cardiac Remodelling, and Quality of Life After Atrial Fibrillation Ablation: Insights From the China‐ AF Registry},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70740}
}
EUVIMED